Peptidomimetic Probes and Molecular Modeling Suggest That Alzheimer's γ-Secretase Is an Intramembrane-Cleaving Aspartyl Protease
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The amyloid beta-protein (Abeta), implicated in the pathogenesis of Alzheimer's disease (AD), is a proteolytic metabolite generated by the sequential action of beta- and gamma-secretases on the amyloid precursor protein (APP). The two main forms of Abeta are 40- and 42-amino acid C-terminal variants, Abeta40 and Abeta42. We recently described a difluoro ketone peptidomimetic (1) that blocks Abeta production at the gamma-secretase level [Wolfe, M. S., et al. (1998) J. Med. Chem. 41, 6-9]. Although designed to inhibit Abeta42 production, 1 also effectively blocked Abeta40 formation. Various amino acid changes in 1 still resulted in inhibition of Abeta40 and Abeta42 production, suggesting relatively loose sequence specificity by gamma-secretase. The alcohol counterparts of selected difluoro ketones also lowered Abeta levels, indicating that the ketone carbonyl is not essential for activity and suggesting that these compounds inhibit an aspartyl protease. Selected compounds inhibited the aspartyl protease cathepsin D but not the cysteine protease calpain, corroborating previous suggestions that gamma-secretase is an aspartyl protease with some properties similar to those of cathepsin D. Also, since the gamma-secretase cleavage sites on APP are within the transmembrane region, we consider the hypothesis that this region binds to gamma-secretase as an alpha-helix and discuss the implications of this model for the mechanism of certain forms of hereditary AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [16]
Citations
Cites
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774
Amyloid, the presenilins and Alzheimer’s disease
Hardy, J. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01030-2 · Cited by 1,370
Cell Biology of the Amyloid beta-Protein Precursor and the Mechanism of Alzheimer's Disease
Selkoe, D. J. (1994) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.10.110194.002105 · Cited by 747
Self-citationRawson, R. B., Zelenski, N. G., Nijhawan, D., Ye, J., Sakai, J., Hasan, M. T., Chang, T. Y., Brown, M. S., & Goldstein, J. L. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80006-4 · Cited by 429
Intracellular Generation and Accumulation of Amyloid β-Peptide Terminating at Amino Acid 42
Wild-Bode, C., Yamazaki, T., Capell, A., Leimer, U., Steiner, H., Ihara, Y., & Haass, C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.26.16085 · Cited by 303
Leonhard, K., Herrmann, J. M., Stuart, R. A., Mannhaupt, G., Neupert, W., & Langer, T. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00796.x · Cited by 286
A Substrate-Based Difluoro Ketone Selectively Inhibits Alzheimer's γ-Secretase Activity
Wolfe, M. S., Citron, M., Diehl, T. S., Xia, W., Donkor, I. O., & Selkoe, D. J. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970621b · Cited by 215
Self-citationInhibition and catalytic mechanism of HIV-1 aspartic protease
Silva, A. M., Cachau, R. E., Sham, H. L., & Erickson, J. W. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0026 · Cited by 178
Klafki, H.-W., Abramowski, D., Swoboda, R., Paganetti, P. A., & Staufenbiel, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.45.28655 · Cited by 159
Cleavage at the amino and carboxyl termini of Alzheimer's amyloid-beta by cathepsin D
Ladror, U. S., Snyder, S. W., Wang, G. T., Holzman, T. F., & Krafft, G. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32325-6 · Cited by 129
Research works printed but not linked: 36
- Tomita T., 1998, Neuroreport 9, 911−3
- Ross S. L., 1998, J. Biol. Chem., 273
- Selkoe D. J., 1997, Science 275, 630−1
- Hardy, 2095, J. (1997)
- Roher A. E., 1993, Proc. Natl. Acad. Sci. U.S.A. 90, 10836−40
- Jarrett J. T., 1993, Biochemistry 32, 4693−7
- Selkoe D. J., 1998, Abstract 8.3.
- Fehrentz J.-A., 1983, Synthesis, 676−8
- Xia W., 1997, J. Biol. Chem., 272
- Citron M., 1996, Proc. Natl. Acad. Sci. U.S.A. 93, 13170−5
- Johnson-Wood K., 1997, Proc. Natl. Acad. Sci. U.S.A. 94, 1550−5
- Seubert P., 1992, Nature 359, 325−7
- Buroker-Kilgore M., 1993, Anal. Biochem. 208, 387−92
- Weidemann A., 1989, Cell 57, 115−26
- Cook D. G., 1997, 3, 1021−3
- Hartmann T., 1997, 3, 1016−20
- Hardy J., 1997, Trends Neurosci. 20, 154−9
- Sakai J., 1996, Cell 85, 1037−46
- Schroeter E. H., 1998, Nature 393, 382−6
- Higaki J., 1995, Neuron 14, 651−9
- Wang K. K., 1990, Trends Pharmacol. Sci. 11, 139−42
- Mellgren R. L., 1997, Biochem. Biophys. Res. Commun. 236, 555−8
- Evin G., 1995, Biochemistry 34, 14185−92
- Doherty A. M., 1992, J. Med. Chem., 35, 14
- Maruyama K., 1996, Biochem. Biophys. Res. Commun. 227, 730−5
- Lichtenthaler S. F., 1997, Biochemistry 36, 15396−403
- Yamazaki T., 1997, Biochemistry 36, 8377−83
- Haass C., 1992, Nature 357, 500−3
- Parris K. D., 1992, Biochemistry 31, 8125−41
- James M. N., 1992, Biochemistry 31, 3872−86
- Veerapandian B., 1992, Protein Sci. 1, 322−8
- Takahashi L. H., 1989, J. Am. Chem. Soc., 111
- Duncan E. A., 1998, J. Biol. Chem., 273
- Walz T., 1997, Nature 387, 624−7
- Cheng A., 1997, Nature 387, 627−30
- Wolfe M. S., 1999, Nature (in press)
Cited by
Items 201–293 of 293
Mechanisms of peptide hydrolysis by aspartyl and metalloproteases
Paul, T. J., Barman, A., Özbil, M., Bora, R. P., Zhang, T., Sharma, G., Hoffmann, Z., & Prabhakar, R. S. (2016) · Physical Chemistry Chemical Physics · doi:10.1039/c6cp02097f · Cited by 16
Inhibitors of rhomboid proteases
Wolf, E. V., & Verhelst, S. H. L. (2015) · Biochimie · doi:10.1016/j.biochi.2015.07.007 · Cited by 16
Cathepsin D Polymorphism in Italian Elderly Subjects with Sporadic Late-Onset Alzheimer’s Disease
Ingegni, T., Nocentini, G., Mariani, E., Spazzafumo, L., Polidori, M. C., Cherubini, A., Catani, M., Cadini, D., Senin, U., & Mecocci, P. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000071003 · Cited by 20
Recent Advances in the Understanding of the Processing of APP to Beta Amyloid Peptide
SINHA, S., ANDERSON, J., JOHN, V., McCONLOGUE, L., BASI, G., THORSETT, E., & SCHENK, D. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06923.x · Cited by 12
Cyclohexyl Ketone Inhibitors of Pin1 Dock in a Trans-Diaxial Cyclohexane Conformation
Xu, G. G., Slebodnick, C., & Etzkorn, F. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044226 · Cited by 15
Structure-activity relationship of presenilin in γ-secretase-mediated intramembrane cleavage
Cai, T., & Tomita, T. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.02.006 · Cited by 16
Cheng, S., Wani, W. Y., Hottman, D. A., Jeong, A., Cao, D., LeBlanc, K. J., Säftig, P., Zhang, J., & Li, L. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14048 · Cited by 16
The discovery of proteases and intramembrane proteolysis
Paschkowsky, S., Hsiao, J. M., Young, J. C., & Munter, L. M. (2019) · Biochemistry and Cell Biology · doi:10.1139/bcb-2018-0186 · Cited by 14
Chapter 4. Secretase inhibitors as therapeutics for Alzheimer's disease
Olson, R. E., & Thompson, L. A. (2000) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(00)35005-9 · Cited by 16
Babušíková, E., Dobrota, D., Turner, A. J., & Nalivaeva, N. N. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921060067 · Cited by 17
Ball, D. W., & Leach, S. D. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-48158-8_4 · Cited by 13
Chapter 5. Secretase inhibitors for Alzheimer's disease
Kornilova, A. Y., & Wolfe, M. S. (2003) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(03)38006-6 · Cited by 14
Self-citationMurphy, M. P., Uljon, S., Golde, T. E., & Wang, R. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(01)00098-9 · Cited by 13
Carter, D. B., Dunn, E., Pauley, A. M., McKinley, D. D., Fleck, T. J., Ellerbrock, B. R., Stratman, N. C., Zhou, X., Himes, C. S., Nye, J. S., et al. (2008) · Molecular Neurodegeneration · doi:10.1186/1750-1326-3-6 · Cited by 11
The role of presenilins in γ‐secretase activity: catalyst or cofactor?
Small, D. H. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00246.x · Cited by 11
Secretases as targets for beta‐amyloid lowering drugs
Walter, J., & Haass, C. (2002) · Drug Development Research · doi:10.1002/ddr.10076 · Cited by 11
“Pharmacological inhibition of g-secretase with peptidomimetic probes suggested that this enzyme is an aspartyl protease [Wolfe et al., 1999b; Moore et al., 2000; Shearman et al., 2000].”
InfluentialKobata, A. (2004) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.01.023 · Cited by 10
The physiological role of presenilins in cellular differentiation: lessons from model organisms
Baumeister, R. (1999) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060050100 · Cited by 9
Design of Substrate Transmembrane Mimetics as Structural Probes for γ-Secretase
Bhattarai, S., Devkota, S., Meneely, K. M., Xing, M., Douglas, J. T., & Wolfe, M. S. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b13405 · Cited by 9
Self-citationChemical Tools for the Study of Intramembrane Proteases
Nguyễn, M. T., Kersavond, T. V., & Verhelst, S. H. L. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00693 · Cited by 8
Selkoe, D. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00067-x · Cited by 9
Self-citationGuha, I., Bhuniya, A., Shukla, D., Patidar, A., Nandi, P. S., Saha, A., Dasgupta, S., Ganguly, N., Ghosh, S., Nair, A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00898 · Cited by 8
Targeting γ-secretase for familial Alzheimer’s disease
Wolfe, M. S. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-021-02744-3 · Cited by 8
Self-citationMembrane-assisted Aβ40 aggregation pathways
Muhammedkutty, F. N. K., & Zhou, H. (2025) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2025.102436 · Cited by 9
Amyloid β Hypothesis in the Development of Therapeutic Agents for Alzheimer’s Disease
Adeniji, A. O., Adams, P. W., & Mody, V. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802810-0.00007-6 · Cited by 13
γ-Secretase--Intramembrane Protease with a Complex
Wolfe, M. S. (2003) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2003.11.pe7 · Cited by 10
Self-citationAmyloid-independent pathogenesis for Alzheimer’s disease: implications for drug design
Wolfe, M. S. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03261-9 · Cited by 6
Self-citationMatsuhisa, K., Saito, A., Cai, L., Kaneko, M., Okamoto, T., Sakaue, F., Asada, R., Urano, F., Yanagida, K., Okochi, M., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201901748r · Cited by 6
Lack of association of cathepsin D genetic polymorphism with Alzheimer's disease in Koreans
Jhoo, J. H., Park, W., Kim, K. W., Lee, K. H., Lee, D. Y., Youn, J. C., Choo, I. H., Seo, J. S., & Woo, J. I. (2005) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2004.12.003 · Cited by 6
“Cathepsin D (CatD) is a major lysosomal/endosomal aspartic protease, which is known to be involved in the amyloid precursor protein processing (Sadik et al., 1999; Wolfe et al., 1999) and the hyperphosphorylated tau formation (Bi et al.”
BackgroundSelecting cells with different Alzheimer's disease γ‐secretase activity using FACS
Sernee, M. F., Evin, G. M., Culvenor, J. G., Villadangos, J. A., Beyreuther, K. T., Masters, C. L., & Cappai, R. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03405.x · Cited by 6
A domain at the C‐terminus of PS1 is required for presenilinase and γ‐secretase activities
Brunkan, A. L., Martinez, M., Wang, J., Walker, E. S., & Goate, A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02945.x · Cited by 7
β‐Amyloid Therapeutic Strategies for Alzheimer's Disease
Imbimbo, B. P., & Speroni, F. (2005) · Wiley eBooks · doi:10.1002/0471266949.bmc112 · Cited by 6
Bhattarai, S., Devkota, S., & Wolfe, M. S. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01395 · Cited by 5
Self-citationPeptide-based, irreversible inhibitors of γ-secretase activity
Piper, S. C., Amtul, Z., Galinanes-Garcia, L., HOWARD, V. G., Ziani‐Cherif, C., McLendon, C., Rochette, M. J., Fauq, A. H., Golde, T. E., & Murphy, M. P. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00828-3 · Cited by 5
Computational Insights into the Development of Novel Therapeutic Strategies for Alzheimer’s Disease
Prabhakar, R. S. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.10 · Cited by 5
Papassotiropoulos, A., Bagli, M., Jessen, F., Maier, W., Förstl, H., Kurz, A., & Heun, R. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000699 · Cited by 5
An Empirical Model of γ‐Secretase Activity
MURPHY, M. P., Wang, R., Fraser, P. E., Fauq, A. H., & Golde, T. E. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06928.x · Cited by 4
γ-Secretase Inhibitors: From Chemical Probes to Drug Development
Hur, J., Gertsik, N., Johnson, D. S., & Li, Y.-M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00004-6 · Cited by 4
The presenilins as potential drug targets in Alzheimer’s disease
Cupers, P., Annaert, W. G., & Strooper, B. D. (1999) · Emerging Therapeutic Targets · doi:10.1517/14728222.3.3.413 · Cited by 3
Computational Modeling of Gamma-Secretase Inhibitors as Anti-Alzheimer Agents
Manoharan, P., & Ghoshal, N. (2017) · Neuromethods · doi:10.1007/978-1-4939-7404-7_12 · Cited by 3
Cawley, N. X., Portela‐Gomes, G. M., Lou, H. X., & Loh, Y. P. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0121 · Cited by 3
Craft, D., Wein, L. M., & Selkoe, D. J. (2005) · International series in management science/operations research/International series in operations research & management science · doi:10.1007/1-4020-8066-2_32 · Cited by 4
Self-citationSubstrate-based chemical probes for Alzheimer’s γ-secretase
Wolfe, M. S. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02565-w · Cited by 4
Self-citationO’Neill, M. J. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.10.1369 · Cited by 2
“Several companies are working on the area and many have patented inhibitors [4-9], some with low nanomolar potency were described (Figure 1).”
BackgroundAspartic Proteases of Alzheimer’s Disease: β- and γ-Secretases
Wolfe, M. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.10077-x · Cited by 2
Self-citationThe γ-secretase complex: from discovery to a therapeutic target
Malvankar, S. R., & Wolfe, M. S. (2026) · RSC Chemical Biology · doi:10.1039/d6cb00022c · Cited by 1
“37 It was then discovered 38 and further confirmed 3,9,40 that two conserved transmembrane aspartates in presenilins are critical for g -secretase cleavage activity.”
Self-citationFrom mechanism to substratome: Unraveling mysteries of γ-secretase
Steiner, H., Breimann, S., Kamp, F., & Frishman, D. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113287 · Cited by 1
Frontiers in Clinical Drug Research - Alzheimer Disorders
Atta-ur-rahman, Mavoungou, C., Zimmerman, K. S., Wright, J., Harding, J., Cavallaro, R., Fuso, A., Yoshiyama, Y., Asija, Z., Clifford, A., et al. (2015) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/97816810806801150301 · Cited by 1
The Biology of the Presenilin Complexes
Wakabayashi, T., Iwatsubo, T., & Strooper, B. D. (2007) · Springer eBooks · doi:10.1007/978-0-387-35135-3_3 · Cited by 2
Singh, P. K., & Donnenberg, M. S. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2203480 · Cited by 1
Glycobiology in the Field of Gerontology (Glycogerontology)
Kobata, A. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-7877-6_21 · Cited by 1
“Currently, it is proposed as a scenario that APP is first cleaved at its b-site by b-secretase [55–58], forms a complex with presenilins, and is cleaved at the g-site by the protease postulated to reside in presenilins [ 58 ].”
BackgroundWolfe, M. S. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382219-2.00065-x · Cited by 1
Self-citationCraft, D., Wein, L. M., & Selkoe, D. J. (2011) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 1
Self-citationHamblett, C. L., Shah, S., Heidebrecht, R. W., & Muñoz, B. (2010) · Methods and principles in medicinal chemistry · doi:10.1002/9783527630943.ch13 · Cited by 1
Modelling of potentially promising SARS protease inhibitors
Plewczyński, D., Hoffmann, M., von Grotthuss, M., Kniżewski, Ł., Rychewski, L., Eitner, K., & Ginalski, K. (2007) · Journal of Physics Condensed Matter · doi:10.1088/0953-8984/19/28/285207 · Cited by 1
Metabolic Abnormalities in Alzheimer Disease
Gebhardt, F. M., & Dodd, P. R. (2008) · Springer eBooks · doi:10.1007/978-0-387-79112-8_22 · Cited by 2
“γ -Secretase is a transmembrane aspartyl protease and belongs to the family of intramembrane cleaving proteases (I-CLiPs) that cleave proteins within the lipid bilayer (Wolfe et al., 1999a) .”
BackgroundIntramembrane proteolysis by the aspartic protease SPP
Lemberg, M. K. (2003) · PubMed · doi:10.3929/ethz-a-004680007
“(Wolfe et al., 1999b).”
BackgroundStrooper, B. D., Herreman, A., Cupers, P., Craessaerts, K., Serneels, L., & Annaert, W. G. (2001) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-662-04399-8_9
Thinking Outside the Box in Alzheimer Disease Treatment
Castellani, R. J., Marlatt, M. W., Nunomura, A., Moreira, P. I., Lee, H., Casadesús, G., Zhu, X., Perry, G. L., & Smith, M. A. (2011) · Wiley eBooks · doi:10.1002/9780470571224.pse457
Identification of a BACE dimer and characterization of its biochemical and enzymatic properties
Westmeyer, G. G. (2006) · doi:10.5282/edoc.5969 · Cited by 1
Role of the 39-kDa receptor-associated protein (RAP) in Alzheimer's disease
Hoang, T. (2012) · UTAS Research Repository · doi:10.25959/23206328 · Cited by 1
γ-Secretase Mediated Proteolysis: At the Cutting Edge of Notch Signaling
Ilagan, M. X. G., Chandu, D., & Kopan, R. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6311-4_7
Therapeutic Opportunities in Alzheimer Disease: Current Concepts
Marlatt, M. W., Moreira, P. I., Lee, H., Casadesús, G., Castellani, R. J., Takeda, A., Nunomura, A., Zhu, X., Perry, G. L., & Smith, M. A. (2010) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/978160805207310904010767
Dettmer, U. (2010) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.11933
Cell Biology of Amyloidogenesis: An overview
Selkoe, D. J., Xia, W., Kimberly, W. T., Vekrellis, K., Walsh, D. M., Esler, W. P., & Wolfe, M. S. (2002) · Advances in behavioral biology · doi:10.1007/978-0-306-47593-1_1
Self-citationder Fakultät, D., & München, L.-M.-U. (2008)
The Complex Pathways to Mechanism-Based Therapeutics in Alzheimer’s Disease
Selkoe, D. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00001-0
Self-citationGolde, T. E., Lessard, C. B., & Ran, Y. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00005-8
Assays for Amyloid Precursor Protein γ-Secretase Activity
Xia, W., Wolfe, M. S., & Campbell, W. A. (2004) · CRC Press eBooks · doi:10.1201/9780203492185.ch5
Self-citationMasters, C. L., & Beyreuther, K. T. (2001) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-662-04399-8_1 · Cited by 2
Primary Prevention of Alzheimer’s Disease
Friel, H., & Frautschy, S. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812259-4.00003-5
de dans la maladie d'Alzheimer
Sévalle, J. (2009)
Potential Treatments for Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00008-2 · Cited by 2
Babušíková, E., Dobrota, D., Тернер, Э. Д. Ж., & Nalivaeva, N. N. (2021) · Biochemistry (Moscow) · doi:10.31857/s0320972521060063
Wolfe, M. S. (2008) · Wiley eBooks · doi:10.1002/9780470048672.wecb258
Self-citationWolfe, M. S. (2004) · Elsevier eBooks · doi:10.1016/b978-0-12-079611-3.50068-9
Self-citationγ-Secretase as a Target for Alzheimer's Disease
Wolfe, M. S. (2007) · Springer eBooks · doi:10.1007/978-0-387-71522-3_8
Self-citationAspartic Proteases of Alzheimer's Disease: β- and γ--Secretases
Wolfe, M. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.10077-x
Self-citationAmyloid β hypothesis in the development of therapeutic agents for Alzheimer's disease
Adeniji, A. O., Johnson, C., & Mody, V. V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30008-0.00020-x
A study of the role of presenilin (1) in regulating synaptic function at hippocampal synapses
Yu, L. M. Y. (2010) · UCL Discovery (University College London)
GXGD-Type Intramembrane Proteases
Steiner, H., & Haass, C. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6311-4_3
Presenilins, APP, and Notch: Proteolysis from Womb to Tomb
Wolfe, M. S., Esler, W. P., Kimberly, W. T., & Selkoe, D. J. (2002) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-642-55996-9_6
Self-citationRôle des ADAM dans le processus physiopathologique de la maladie d'Alzheimer
Laumet, G. O. (2010) · theses.fr (ABES) · doi:10.70675/94126786zf990z488ezb471z5f1d5686766c · Cited by 1
Physiological and pathological roles of the amyloid precursor protein at the presynapse
Jordá-Siquier, T. (2021) · theses.fr (ABES) · doi:10.70675/3bff9a77z3935z4d28zb02bz5b454bcbc77e
BindingDB (2009) · UC San Diego · doi:10.7270/q2wd405k
BindingDB (2012) · UC San Diego · doi:10.7270/q2fb53qn
γ-Secretase And Alzheimer’S Disease
Wolfe, M. S. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6311-4_6
Self-citation
Metadata
- Authors
- Wolfe, M. S., Xia, W., Moore, C. L., Leatherwood, D. D., Ostaszewski, B., Rahmati, T., Donkor, I. O., & Selkoe, D. J.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Wolfe, Michael S.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1999-03-26
- Volume
- 38
- Issue
- 15
- Pages
- 4720-4727
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2004305803
- Cited by
- 289
- References
- 12
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 1 · 2021: 8 · 2020: 8 · 2019: 5 · 2018: 2 · 2017: 8 · 2016: 7 · 2015: 5 · 2014: 3 · 2013: 4 · 2012: 5
- FWCI
- 17.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (7r29ns037537-02)
- National Institute on Aging (AG 12749, R01AG012749)
- National Heart, Lung, and Blood Institute (HL 3536)
- National Institute of Neurological Disorders and Stroke (NS37537)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Keywords
- gamma-secretase, Alzheimer's disease, amyloid-beta, aspartic protease, intramembrane cleavage, amyloid precursor protein, cathepsin D, calpain, transmembrane helices, enzyme inhibition
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Humans, Hydrolysis, Ketones, Models, Molecular, Molecular Sequence Data, Endopeptidases, Protease Inhibitors, Protein Binding, Molecular Probes, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Molecular Mimicry, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.